Download PDF
Semin Thromb Hemost
DOI: 10.1055/s-0045-1809162
Review Article

Global Hemostasis Testing in Chronic Kidney Disease—Are They Better Predictors of Bleeding and Thrombosis Risk?

Hui Yin Lim 
1   Northern Clinical Diagnostics and Thrombovascular Research (NECTAR), Northern Health, Epping, Victoria, Australia
2   Department of Hematology, Northern Pathology Victoria, Northern Health, Epping, Victoria, Australia
3   Department of Medicine, Northern Health, University of Melbourne, Heidelberg, Victoria, Australia
,
Eng Soo Yap
4   Department of Laboratory Medicine, National University Hospital, Singapore
5   Department of Laboratory Medicine, Ng Teng Fong Hospital, Singapore
,
Prahlad Ho
1   Northern Clinical Diagnostics and Thrombovascular Research (NECTAR), Northern Health, Epping, Victoria, Australia
2   Department of Hematology, Northern Pathology Victoria, Northern Health, Epping, Victoria, Australia
3   Department of Medicine, Northern Health, University of Melbourne, Heidelberg, Victoria, Australia
› Author Affiliations
Funding H.Y.L. is a Melbourne Postdoctoral Fellow (University of Melbourne, Australia).
› Further Information
   Permissions and Reprints

Abstract

Chronic kidney disease (CKD) affects over 10% of the global population and significantly increases the risk of cardiovascular disease as well as arising bleeding. There are alterations in hemostasis, which are multifactorial, involving complex interactions between coagulation, platelets, and the vessel wall. Hemostasis evaluation in CKD is critical for the optimal management of patients. However, conventional coagulation testing and renal function do not fully reflect the hemostatic alterations and do not adequately represent the risk of bleeding and/or thrombosis in patients with CKD. Global hemostatic assays, including thrombin and fibrin generation assays, provide a more wholesome assessment of the process, including the interaction between procoagulants, anticoagulants, platelets, and fibrinolysis. This review critically appraises published studies reporting the use of global coagulation assays to evaluate hemostasis in patients with CKD, as well as associated clinical outcomes.

Keywords

chronic kidney disease - hemostasis - bleeding - cardiovascular disease - thrombin - fibrin


Publication History

Article published online:
15 May 2025

© 2025. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Zoccali C, Mallamaci F, Adamczak M. et al. Cardiovascular complications in chronic kidney disease: a review from the European Renal and Cardiovascular Medicine Working Group of the European Renal Association. Cardiovasc Res 2023; 119 (11) 2017-2032
    PubMedSearch in Google Scholar
  • 2 Park S, Choi YJ, Kang JE. et al. P2Y12 Antiplatelet choice for patients with chronic kidney disease and acute coronary syndrome: A systematic review and meta-analysis. J Pers Med 2021; 11 (03) 222
    PubMedSearch in Google Scholar
  • 3 Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004; 164 (06) 659-663
    CrossrefPubMedSearch in Google Scholar
  • 4 Alkhalil M, McCune C, McClenaghan L. et al. Comparative analysis of the effect of renal function on the spectrum of coronary artery disease. Am J Med 2020; 133 (11) e631-e640
    PubMedSearch in Google Scholar
  • 5 Liang CC, Wang SM, Kuo HL. et al. Upper gastrointestinal bleeding in patients with CKD. Clin J Am Soc Nephrol 2014; 9 (08) 1354-1359
    CrossrefPubMedSearch in Google Scholar
  • 6 Holzmann MJ, Aastveit A, Hammar N, Jungner I, Walldius G, Holme I. Renal dysfunction increases the risk of ischemic and hemorrhagic stroke in the general population. Ann Med 2012; 44 (06) 607-615
    PubMedSearch in Google Scholar
  • 7 Molnar AO, Bota SE, Garg AX. et al. The risk of major hemorrhage with CKD. J Am Soc Nephrol 2016; 27 (09) 2825-2832
    CrossrefPubMedSearch in Google Scholar
  • 8 Sood MM, Bota SE, McArthur E. et al. The three-year incidence of major hemorrhage among older adults initiating chronic dialysis. Can J Kidney Health Dis 2014; 1: 21
    CrossrefPubMedSearch in Google Scholar
  • 9 Stenvinkel P. Chronic kidney disease: a public health priority and harbinger of premature cardiovascular disease. J Intern Med 2010; 268 (05) 456-467
    PubMedSearch in Google Scholar
  • 10 Carrero JJ, Stenvinkel P. Inflammation in end-stage renal disease–what have we learned in 10 years?. Semin Dial 2010; 23 (05) 498-509
    PubMedSearch in Google Scholar
  • 11 Zhang YX, Tang RN, Wang LT, Liu BC. Role of crosstalk between endothelial cells and smooth muscle cells in vascular calcification in chronic kidney disease. Cell Prolif 2021; 54 (03) e12980
    PubMedSearch in Google Scholar
  • 12 Lutz J, Menke J, Sollinger D, Schinzel H, Thürmel K. Haemostasis in chronic kidney disease. Nephrol Dial Transplant 2014; 29 (01) 29-40
    CrossrefPubMedSearch in Google Scholar
  • 13 Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003; 108 (24) 2957-2963
    PubMedSearch in Google Scholar
  • 14 Crow MK. Type I interferon in systemic lupus erythematosus. Curr Top Microbiol Immunol 2007; 316: 359-386
    PubMedSearch in Google Scholar
  • 15 Karnati S, Seimetz M, Kleefeldt F. et al. Chronic obstructive pulmonary disease and the cardiovascular system: Vascular repair and regeneration as a therapeutic target. Front Cardiovasc Med 2021; 8: 649512
    PubMedSearch in Google Scholar
  • 16 Thakur M, Junho CVC, Bernhard SM, Schindewolf M, Noels H, Döring Y. NETs-induced thrombosis impacts on cardiovascular and chronic kidney disease. Circ Res 2023; 132 (08) 933-949
    CrossrefPubMedSearch in Google Scholar
  • 17 Takagi M, Wada H, Mukai K. et al. Increased activated protein C: protein C inhibitor complex and decreased protein C inhibitor levels in patients with chronic renal failure on maintenance hemodialysis. Clin Appl Thromb Hemost 1999; 5 (02) 113-116
    PubMedSearch in Google Scholar
  • 18 Yu M, Xie R, Zhang Y. et al. Phosphatidylserine on microparticles and associated cells contributes to the hypercoagulable state in diabetic kidney disease. Nephrol Dial Transplant 2018; 33 (12) 2115-2127
    PubMedSearch in Google Scholar
  • 19 Mörtberg J, Lundwall K, Mobarrez F, Wallén H, Jacobson SH, Spaak J. Increased concentrations of platelet- and endothelial-derived microparticles in patients with myocardial infarction and reduced renal function- a descriptive study. BMC Nephrol 2019; 20 (01) 71
    PubMedSearch in Google Scholar
  • 20 Shlipak MG, Fried LF, Crump C. et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 2003; 107 (01) 87-92
    CrossrefPubMedSearch in Google Scholar
  • 21 Brunet P, Aillaud MF, San Marco M. et al. Antiphospholipids in hemodialysis patients: relationship between lupus anticoagulant and thrombosis. Kidney Int 1995; 48 (03) 794-800
    PubMedSearch in Google Scholar
  • 22 Jessica C, Kevin V, Marie VA. et al. A comparative study on the haemostatic changes in kidney failure patients: Pre- and post-haemodialysis and haemodiafiltration. Thromb Res 2024; 242: 109120
    PubMedSearch in Google Scholar
  • 23 Heymann EP, Penny H, Goldsmith DJA. Vascular and arterial calcification in peritoneal dialysis patients–state-of-the-art 2012. Contrib Nephrol 2012; 178: 189-194
    PubMedSearch in Google Scholar
  • 24 Krediet RT, Balafa O. Cardiovascular risk in the peritoneal dialysis patient. Nat Rev Nephrol 2010; 6 (08) 451-460
    PubMedSearch in Google Scholar
  • 25 Rao NN, Coates PT. Cardiovascular disease after kidney transplant. Semin Nephrol 2018; 38 (03) 291-297
    PubMedSearch in Google Scholar
  • 26 Verhave JC, Tagalakis V, Suissa S, Madore F, Hébert MJ, Cardinal H. The risk of thromboembolic events in kidney transplant patients. Kidney Int 2014; 85 (06) 1454-1460
    PubMedSearch in Google Scholar
  • 27 Huang MJ, Wei RB, Wang Y. et al. Blood coagulation system in patients with chronic kidney disease: a prospective observational study. BMJ Open 2017; 7 (05) e014294
    PubMedSearch in Google Scholar
  • 28 Nikolova-Vlahova M, Petrova Baleva M, Nikolov PK. Thromboembolism in renal diseases. In: Firstenberg MS. ed. Embolic Diseases - Unusual Therapies and Challenges. IntechOpen; 2017: 68486
    Search in Google Scholar
  • 29 Holden RM, Harman GJ, Wang M, Holland D, Day AG. Major bleeding in hemodialysis patients. Clin J Am Soc Nephrol 2008; 3 (01) 105-110
    PubMedSearch in Google Scholar
  • 30 Noris M, Remuzzi G. Uremic bleeding: closing the circle after 30 years of controversies?. Blood 1999; 94 (08) 2569-2574
    PubMedSearch in Google Scholar
  • 31 Molino D, De Lucia D, Gaspare De Santo N. Coagulation disorders in uremia. Semin Nephrol 2006; 26 (01) 46-51
    CrossrefPubMedSearch in Google Scholar
  • 32 Kaw D, Malhotra D. Platelet dysfunction and end-stage renal disease. Semin Dial 2006; 19 (04) 317-322
    PubMedSearch in Google Scholar
  • 33 Di Minno G, Martinez J, McKean ML, De La Rosa J, Burke JF, Murphy S. Platelet dysfunction in uremia. Multifaceted defect partially corrected by dialysis. Am J Med 1985; 79 (05) 552-559
    CrossrefPubMedSearch in Google Scholar
  • 34 Holden RM, Tuttle A, Burbidge T. et al. Quantitative and qualitative changes of von Willebrand factor and their impact on mortality in patients with end-stage kidney disease. Blood Coagul Fibrinolysis 2013; 24 (07) 719-726
    PubMedSearch in Google Scholar
  • 35 Pavlou EG, Georgatzakou HT, Fortis SP. et al. Coagulation abnormalities in renal pathology of chronic kidney disease: The interplay between blood cells and soluble factors. Biomolecules 2021; 11 (09) 1309
    CrossrefPubMedSearch in Google Scholar
  • 36 Livio M, Gotti E, Marchesi D, Mecca G, Remuzzi G, de Gaetano G. Uraemic bleeding: role of anaemia and beneficial effect of red cell transfusions. Lancet 1982; 2 (8306): 1013-1015
    CrossrefPubMedSearch in Google Scholar
  • 37 Viganò G, Benigni A, Mendogni D, Mingardi G, Mecca G, Remuzzi G. Recombinant human erythropoietin to correct uremic bleeding. Am J Kidney Dis 1991; 18 (01) 44-49
    CrossrefPubMedSearch in Google Scholar
  • 38 Besarab A, Bolton WK, Browne JK. et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339 (09) 584-590
    CrossrefPubMedSearch in Google Scholar
  • 39 Frelinger III AL, Grace RF, Gerrits AJ. et al. Platelet function tests, independent of platelet count, are associated with bleeding severity in ITP. Blood 2015; 126 (07) 873-879
    CrossrefPubMedSearch in Google Scholar
  • 40 Friedmann AM, Sengul H, Lehmann H, Schwartz C, Goodman S. Do basic laboratory tests or clinical observations predict bleeding in thrombocytopenic oncology patients? A reevaluation of prophylactic platelet transfusions. Transfus Med Rev 2002; 16 (01) 34-45
    CrossrefPubMedSearch in Google Scholar
  • 41 Baaten CCFMJ, Sternkopf M, Henning T, Marx N, Jankowski J, Noels H. Platelet function in CKD: A systematic review and meta-analysis. J Am Soc Nephrol 2021; 32 (07) 1583-1598
    CrossrefPubMedSearch in Google Scholar
  • 42 Mann KG, Brummel K, Butenas S. What is all that thrombin for?. J Thromb Haemost 2003; 1 (07) 1504-1514
    CrossrefPubMedSearch in Google Scholar
  • 43 Chee YL, Greaves M. Role of coagulation testing in predicting bleeding risk. Hematol J 2003; 4 (06) 373-378
    PubMedSearch in Google Scholar
  • 44 Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med 2011; 365 (02) 147-156
    CrossrefPubMedSearch in Google Scholar
  • 45 Rautou PE, Caldwell SH, Villa E. Bleeding and thrombotic complications in patients with cirrhosis: A state-of-the-art appraisal. Clin Gastroenterol Hepatol 2023; 21 (08) 2110-2123
    CrossrefPubMedSearch in Google Scholar
  • 46 Lim HY, Lui B, Tacey M. et al. Global coagulation assays in patients with chronic kidney disease and their role in predicting thrombotic risk. Thromb Res 2023; 226: 127-135
    PubMedSearch in Google Scholar
  • 47 Kim JH, Baek CH, Min JY, Kim JS, Kim SB, Kim H. Desmopressin improves platelet function in uremic patients taking antiplatelet agents who require emergent invasive procedures. Ann Hematol 2015; 94 (09) 1457-1461
    PubMedSearch in Google Scholar
  • 48 Brook R, Ho P, Lim HY. Use of global coagulation assays to predict spontaneous major bleeding in chronic kidney disease patients. Paper presented at: International Society of Thrombosis and Hemostasis; June 23, 2024; Bangkok, Thailand.
    PubMed
  • 49 Caruana J, Riva N, Vella K, Davenport A, Gatt A. Navigating through the haemostatic paradox in kidney failure: A practical overview. Br J Haematol 2023; 202 (02) 230-247
    PubMedSearch in Google Scholar
  • 50 Dubin R, Cushman M, Folsom AR. et al. Kidney function and multiple hemostatic markers: cross sectional associations in the multi-ethnic study of atherosclerosis. BMC Nephrol 2011; 12: 3
    PubMedSearch in Google Scholar
  • 51 van der Vorm LN, Visser R, Huskens D. et al. Circulating active von Willebrand factor levels are increased in chronic kidney disease and end-stage renal disease. Clin Kidney J 2019; 13 (01) 72-74
    CrossrefPubMedSearch in Google Scholar
  • 52 Hung SY, Lin TM, Liou HH. et al. Association between ADAMTS13 deficiency and cardiovascular events in chronic hemodialysis patients. Sci Rep 2021; 11 (01) 22816
    PubMedSearch in Google Scholar
  • 53 Soyoral YU, Demir C, Begenik H. et al. Skin bleeding time for the evaluation of uremic platelet dysfunction and effect of dialysis. Clin Appl Thromb Hemost 2012; 18 (02) 185-188
    PubMedSearch in Google Scholar
  • 54 Mohapatra A, Valson AT, Gopal B. et al. Hemostatic abnormalities in severe renal failure: Do they bark or bite?. Indian J Nephrol 2018; 28 (02) 135-142
    PubMedSearch in Google Scholar
  • 55 Ocak G, Rookmaaker MB, Algra A. et al.; SMART Study Group. Chronic kidney disease and bleeding risk in patients at high cardiovascular risk: a cohort study. J Thromb Haemost 2018; 16 (01) 65-73
    CrossrefPubMedSearch in Google Scholar
  • 56 Folsom AR, Lutsey PL, Heckbert SR, Cushman M. Serum albumin and risk of venous thromboembolism. Thromb Haemost 2010; 104 (01) 100-104
    PubMedSearch in Google Scholar
  • 57 Laville SM, Couturier A, Lambert O. et al.; CKD-REIN Study Collaborators. Urea levels and cardiovascular disease in patients with chronic kidney disease. Nephrol Dial Transplant 2022; 38 (01) 184-192
    PubMedSearch in Google Scholar
  • 58 Kujovich JL. Coagulopathy in liver disease: a balancing act. Hematology Am Soc Hematol Educ Program 2015; 2015: 243-249
    PubMedSearch in Google Scholar
  • 59 Lim HY, O'Malley C, Donnan G, Nandurkar H, Ho P. A review of global coagulation assays - Is there a role in thrombosis risk prediction?. Thromb Res 2019; 179: 45-55
    CrossrefPubMedSearch in Google Scholar
  • 60 Hartmann J, Hermelin D, Levy JH. Viscoelastic testing: an illustrated review of technology and clinical applications. Res Pract Thromb Haemost 2022; 7 (01) 100031
    CrossrefPubMedSearch in Google Scholar
  • 61 Meier K, Saenz DM, Torres GL. et al. Thrombelastography suggests hypercoagulability in patients with renal dysfunction and intracerebral hemorrhage. J Stroke Cerebrovasc Dis 2018; 27 (05) 1350-1356
    CrossrefPubMedSearch in Google Scholar
  • 62 Darlington A, Ferreiro JL, Ueno M. et al. Haemostatic profiles assessed by thromboelastography in patients with end-stage renal disease. Thromb Haemost 2011; 106 (01) 67-74
    PubMedSearch in Google Scholar
  • 63 Abdelmaguid A, Roberts LN, Tugores L. et al. Evaluation of novel coagulation and platelet function assays in patients with chronic kidney disease. J Thromb Haemost 2022; 20 (04) 845-856
    PubMedSearch in Google Scholar
  • 64 Sahli SD, Castellucci C, Roche TR, Rössler J, Spahn DR, Kaserer A. The impact of direct oral anticoagulants on viscoelastic testing - A systematic review. Front Cardiovasc Med 2022; 9: 991675
    CrossrefPubMedSearch in Google Scholar
  • 65 Mavrakanas TA, Charytan DM, Winkelmayer WC. Direct oral anticoagulants in chronic kidney disease: an update. Curr Opin Nephrol Hypertens 2020; 29 (05) 489-496
    CrossrefPubMedSearch in Google Scholar
  • 66 Maier CL, Sniecinski RM. Anticoagulation monitoring for perioperative physicians. Anesthesiology 2021; 135 (04) 738-748
    CrossrefPubMedSearch in Google Scholar
  • 67 Dargaud Y, Béguin S, Lienhart A. et al. Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb Haemost 2005; 93 (03) 475-480
    Thieme ConnectPubMedSearch in Google Scholar
  • 68 Gäckler A, Rohn H, Lisman T. et al. Evaluation of hemostasis in patients with end-stage renal disease. PLoS ONE 2019; 14 (02) e0212237
    PubMedSearch in Google Scholar
  • 69 Carcaillon L, Alhenc-Gelas M, Bejot Y. et al. Increased thrombin generation is associated with acute ischemic stroke but not with coronary heart disease in the elderly: the Three-City cohort study. Arterioscler Thromb Vasc Biol 2011; 31 (06) 1445-1451
    PubMedSearch in Google Scholar
  • 70 Schneider JG, Isermann B, Kleber ME. et al. Inverse association of the endogenous thrombin potential (ETP) with cardiovascular death: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Int J Cardiol 2014; 176 (01) 139-144
    PubMedSearch in Google Scholar
  • 71 Tomura S, Nakamura Y, Deguchi F, Ando R, Chida Y, Marumo F. Coagulation and fibrinolysis in patients with chronic renal failure undergoing conservative treatment. Thromb Res 1991; 64 (01) 81-90
    PubMedSearch in Google Scholar
  • 72 Milburn JA, Ford I, Mutch NJ, Fluck N, Brittenden J. Thrombin-anti-thrombin levels and patency of arterio-venous fistula in patients undergoing haemodialysis compared to healthy volunteers: a prospective analysis. PLoS ONE 2013; 8 (07) e67799
    PubMedSearch in Google Scholar
  • 73 Brophy DF, Martin EJ, Gehr TW, Carr Jr ME. Enhanced anticoagulant activity of enoxaparin in patients with ESRD as measured by thrombin generation time. Am J Kidney Dis 2004; 44 (02) 270-277
    PubMedSearch in Google Scholar
  • 74 Collet JP, Allali Y, Lesty C. et al. Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis. Arterioscler Thromb Vasc Biol 2006; 26 (11) 2567-2573
    CrossrefPubMedSearch in Google Scholar
  • 75 Sjøland JA, Sidelmann JJ, Brabrand M. et al. Fibrin clot structure in patients with end-stage renal disease. Thromb Haemost 2007; 98 (02) 339-345
    PubMedSearch in Google Scholar
  • 76 Lim HY, Donnan G, Nandurkar H, Ho P. Global coagulation assays in hypercoagulable states. J Thromb Thrombolysis 2022; 54 (01) 132-144
    CrossrefPubMedSearch in Google Scholar
  • 77 Undas A, Kolarz M, Kopeć G, Tracz W. Altered fibrin clot properties in patients on long-term haemodialysis: relation to cardiovascular mortality. Nephrol Dial Transplant 2008; 23 (06) 2010-2015
    PubMedSearch in Google Scholar
  • 78 Mörtberg J, Blombäck M, Wallén Å, He S, Jacobson SH, Spaak J. Increased fibrin formation and impaired fibrinolytic capacity in severe chronic kidney disease. Blood Coagul Fibrinolysis 2016; 27 (04) 401-407
    PubMedSearch in Google Scholar
  • 79 Lloyd-Donald P, Churilov L, Cheong B. et al. Assessing TEG6S reliability between devices and across multiple time points: A prospective thromboelastography validation study. Sci Rep 2020; 10 (01) 7045
    CrossrefPubMedSearch in Google Scholar
  • 80 Theusinger OM, Nürnberg J, Asmis LM, Seifert B, Spahn DR. Rotation thromboelastometry (ROTEM) stability and reproducibility over time. Eur J Cardiothorac Surg 2010; 37 (03) 677-683
    PubMedSearch in Google Scholar
  • 81 Ninivaggi M, de Laat-Kremers R, Tripodi A. et al. Recommendations for the measurement of thrombin generation: Communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies. J Thromb Haemost 2021; 19 (05) 1372-1378
    PubMedSearch in Google Scholar
  • 82 Wang J, Tan GJ, Han LN, Bai YY, He M, Liu HB. Novel biomarkers for cardiovascular risk prediction. J Geriatr Cardiol 2017; 14 (02) 135-150
    PubMedSearch in Google Scholar
  • 83 Patsouras MD, Vlachoyiannopoulos PG. Evidence of epigenetic alterations in thrombosis and coagulation: A systematic review. J Autoimmun 2019; 104: 102347
    CrossrefPubMedSearch in Google Scholar
  • 84 Chiu H, Wu PY, Huang JC. et al. There is a U shaped association between non high density lipoprotein cholesterol with overall and cardiovascular mortality in chronic kidney disease stage 3-5. Sci Rep 2020; 10 (01) 12749
    PubMedSearch in Google Scholar
  • 85 MacRae JM, Dipchand C, Oliver M. et al.; Canadian Society of Nephrology Vascular Access Work Group. Arteriovenous access failure, stenosis, and thrombosis. Can J Kidney Health Dis 2016; 3: 2054358116669126
    CrossrefPubMedSearch in Google Scholar
  • 86 Mangin PH, Neeves KB, Lam WA. et al.; Subcommittee on Biorheology. In vitro flow-based assay: From simple toward more sophisticated models for mimicking hemostasis and thrombosis. J Thromb Haemost 2021; 19 (02) 582-587
    CrossrefPubMedSearch in Google Scholar
  • 87 Holloway DS, Vagher JP, Caprini JA, Simon NM, Mockros LF. Thrombelastography of blood from subjects with chronic renal failure. Thromb Res 1987; 45 (06) 817-825
    PubMedSearch in Google Scholar
  • 88 Pluta J, Nicińska B, Durlik M, Trzebicki J. Assessment of haemostasis and impact of fibrinogen supplementation on clot properties using global haemostasis assays in patients on chronic dialysis. Anaesthesiol Intensive Ther 2020; 52 (04) 274-280
    PubMedSearch in Google Scholar
  • 89 Ho SJ, Gemmell R, Brighton TA. Platelet function testing in uraemic patients. Hematology 2008; 13 (01) 49-58
    CrossrefPubMedSearch in Google Scholar
  • 90 Pandey CK, Prakash K, Karna ST, Nayak SL, Tandon M, Jain P. Detection of coagulopathy in chronic renal disease using thromboelastography and its comparison with conventional tests. J Assoc Physicians India 2019; 67 (04) 34-37
    PubMedSearch in Google Scholar
  • 91 Jeong JC, Kim JE, Ryu JW, Joo KW, Kim HK. Plasma haemostatic potential of haemodialysis patients assessed by thrombin generation assay: hypercoagulability in patients with vascular access thrombosis. Thromb Res 2013; 132 (05) 604-609
    PubMedSearch in Google Scholar
  • 92 Matusik PT, Heleniak Z, Papuga-Szela E, Plens K, Lelakowski J, Undas A. Chronic kidney disease and its impact on a prothrombotic state in patients with atrial fibrillation. J Clin Med 2020; 9 (08) 2476
    PubMedSearch in Google Scholar
  • 93 Adams MJ, Irish AB, Watts GF, Oostryck R, Dogra GK. Hypercoagulability in chronic kidney disease is associated with coagulation activation but not endothelial function. Thromb Res 2008; 123 (02) 374-380
    PubMedSearch in Google Scholar
  • 94 Burton JO, Hamali HA, Singh R. et al. Elevated levels of procoagulant plasma microvesicles in dialysis patients. PLoS ONE 2013; 8 (08) e72663
    PubMedSearch in Google Scholar
  • 95 Nieuwenhuijs-Moeke GJ, van den Berg TAJ, Bakker SJL. et al. Preemptively and non-preemptively transplanted patients show a comparable hypercoagulable state prior to kidney transplantation compared to living kidney donors. PLoS ONE 2018; 13 (07) e0200537
    PubMedSearch in Google Scholar